Eli Lilly raised UK private Mounjaro prices by up to 170 percent on 1 September 2025. NHS prices are unchanged.

Mounjaro UK Price Increase 2026: Private Prescription Cost Guide

You open the pharmacy bill in October 2025 and the cost of your weekly weight-loss injection has roughly doubled. That was the reality for many of the estimated two million UK adults using Mounjaro privately, compared with about 290,000 receiving it on the NHS. In August 2025 Eli Lilly announced a wholesale price rise of up to 170 percent for private UK prescriptions, effective 1 September. The company put the move down to aligning UK prices with international levels, partly driven by US policy pressure. NHS prices are unchanged. For many private users in 2026, the question is whether to keep paying, reduce dose, switch medication or check NHS eligibility. This guide covers the current pharmacy costs, NHS access rules, alternative treatments, side-effect considerations and the pipeline of new oral GLP-1 medications that may offer future options.

What changed on 1 September 2025

On 14 August 2025 Eli Lilly announced a UK wholesale price increase for Mounjaro of up to 170 percent, effective 1 September 2025. The change applies only to private prescriptions. Wholesale price for a 2.5 mg starter pen rose from about 92 pounds to 133 pounds. The 15 mg maintenance pen rose from about 122 pounds to 330 pounds. Intermediate doses rose proportionately or more steeply. NHS prescriptions are unaffected: the standard NHS prescription charge in England stays at 9.90 pounds per item, frozen for 2026/27, with prescriptions free in Scotland and Wales. Most UK private pharmacies passed the wholesale increase through to patients between October and December 2025. A few, including Pharmacy2U and Boots, temporarily froze prices to honour prepaid courses or to manage a surge in demand as patients tried to stockpile at the old price. Eli Lilly described the move as a realignment of the UK list price with international levels, noting that UK prices had been set below European benchmarks in 2023 and 2024 to help with NHS adoption. For a patient on the 15 mg dose, annual cost more than doubled.

2026 private pharmacy prices for Mounjaro UK

As of May 2026 the typical private monthly cost for Mounjaro across the major UK pharmacies sits between 120 and 340 pounds, depending on dose and provider. Some clinics add a consultation fee of 30 to 50 pounds. The 2.5 mg starter dose is the least expensive, typically 120 to 170 pounds. A 5 mg dose runs 150 to 210 pounds, 7.5 mg 180 to 260 pounds, 10 mg 210 to 290 pounds, 12.5 mg 230 to 310 pounds, and the 15 mg maintenance dose 270 to 340 pounds. Specific providers: Boots Online Doctor 170 to 320 pounds, Superdrug Online Doctor 179 to 299 pounds, Pharmacy2U 165 to 310 pounds, LloydsPharmacy Online Doctor 195 to 340 pounds, Asda Online Doctor 175 to 320 pounds. Smaller online pharmacies sometimes undercut, but always verify the dispensing pharmacy is registered with the General Pharmaceutical Council (GPhC) and that the medication is sourced through legitimate, MHRA-regulated supply chains. Stock availability tightened after the 2025 price change, so comparing prices at the point of a dose increase is a practical step.

NHS Mounjaro access in 2026 and how to check eligibility

NHS access to Mounjaro is currently restricted to a high-risk group known as Cohort 1. Eligibility requires a BMI of 40 or above (or 37.5 or above for South Asian, Black African or Chinese ethnicity) and at least four qualifying comorbidities. These conditions include type 2 diabetes, hypertension, cardiovascular disease, obstructive sleep apnoea, dyslipidaemia and chronic kidney disease. Patients are identified through searches of GP records and contacted directly by local NHS prescribing hubs. You cannot self-refer or request Mounjaro from your GP outside this structured pathway. Of an estimated 3.4 million eligible UK adults, around 250,000 are expected to gain access over three years under a staged rollout. A second cohort, with anticipated lower BMI thresholds, is expected to begin from June 2026. Full nationwide rollout could take up to 12 years. If you think you meet Cohort 1 criteria but have not been contacted, the most useful step is to ensure your GP record accurately lists your BMI, relevant comorbidities and ethnicity. A routine medication review or annual chronic disease review is a sensible time to discuss this.

What to do if your private Mounjaro bill jumped

First, do not stop taking Mounjaro abruptly without speaking to your prescribing clinician. Weight regain after cessation is common. Second, compare current prices across pharmacies using the May 2026 ranges above. Switching provider at the same dose can sometimes save 20 to 60 pounds per month. Third, discuss with your prescriber whether your current dose is still clinically appropriate. If your weight has plateaued at 12.5 mg or 15 mg, a step down to a lower dose may reduce both side effects and cost, but that is a clinical decision, not a financial one alone. Fourth, review your NHS Cohort 1 eligibility and make sure your GP record is up to date. Fifth, if considering alternatives like Wegovy or Saxenda, do so only with clinical input. Sixth, avoid unsafe practices such as stretching pen intervals beyond manufacturer recommendations or sharing pens. Finally, keep a simple diary of weight, blood pressure, HbA1c if relevant and any side effects for your next prescriber review.

Alternatives to Mounjaro in 2026 and the orforglipron pipeline

If private Mounjaro costs are unsustainable, talk these alternatives through with your clinician. Wegovy (semaglutide) is the main injectable GLP-1 alternative. Its private monthly cost is generally lower than 15 mg Mounjaro, though head-to-head trial data shows tirzepatide typically produces more weight loss at maximum doses. Saxenda (liraglutide) is an older daily injection, less effective than newer options. Rybelsus (oral semaglutide) is a tablet licensed for type 2 diabetes and is sometimes used off-label for weight management. Looking ahead, orforglipron, an oral non-peptide GLP-1 from Eli Lilly, has shown strong phase 3 results, with a regulatory decision expected in 2026. Oral semaglutide 25 mg is also under review. If either is approved and competitively priced, these tablets could reshape the private market, since most patients prefer tablets over injections. Non-drug options remain important: NHS tier 3 specialist weight management services, the NHS Diabetes Prevention Programme, and structured commercial programmes can all provide support. Bariatric surgery remains the intervention with the strongest evidence for durable weight loss in severe obesity.

Side effects and long-term safety in 2026

The most common Mounjaro side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, indigestion and abdominal pain. These usually peak after dose increases and tend to settle within two to four weeks. Less common issues include gallstones and gallbladder inflammation. Pancreatitis is a rare but serious concern; clinical trial rates were 0.23 to 0.39 percent. A 2024-25 UK hospital audit found 1.8 percent of pancreatitis admissions involved tirzepatide users, though most had other potential causes, and no cases of chronic pancreatitis were identified. Loss of muscle and bone mass is a recognised risk, particularly in people using the drug off-label who are not obese, those on very low-protein diets, and older adults. Resistance training and adequate protein intake (1.0 to 1.5 grams per kilogram of body weight) are recommended countermeasures. Mounjaro is subject to the MHRA black triangle scheme for enhanced safety monitoring, so all side effects should be reported via the Yellow Card scheme. It is contraindicated in pregnancy, breastfeeding, and in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Long-term safety data beyond three years are still being collected.

Frequently Asked Questions

Why did Mounjaro get so much more expensive in the UK?

Eli Lilly raised UK wholesale prices for Mounjaro by up to 170 percent on 1 September 2025. The company explained the move as aligning UK list price with international price levels, partly under US pricing pressure including the Most Favoured Nation policy. UK list prices had been set well below European levels in 2023 and 2024 to secure NHS rollout. The increase applies to private prescriptions only. NHS prices are unchanged.

How much does Mounjaro cost privately in 2026 in the UK?

About 120 to 340 pounds per month depending on dose and pharmacy, plus consultation fees of 30 to 50 pounds at some providers. Lowest 2.5 mg starter dose: around 120 to 170 pounds. Highest 15 mg dose: around 270 to 340 pounds. Boots, Superdrug, Pharmacy2U, LloydsPharmacy and Asda all sit broadly in this range. Smaller online pharmacies sometimes undercut; always verify GPhC and MHRA registration.

Can I get Mounjaro on the NHS in 2026?

Yes if you meet Cohort 1 criteria. BMI 40 or above (37.5 or above for South Asian, Black African or Chinese ethnicity) and at least four qualifying comorbidities such as type 2 diabetes, hypertension, cardiovascular disease and obstructive sleep apnoea. Patients are identified through GP records and contacted directly through local prescribing hubs. You cannot self-refer. Cohort 2 expansion expected from June 2026 with lower BMI thresholds.

Should I stop Mounjaro because of the price hike?

Speak to your prescriber first. Stopping GLP-1 therapy is associated with weight regain. Before stopping, compare prices across pharmacies, ask whether stepping down a dose is clinically appropriate, check NHS eligibility, and consider alternatives. If you do choose to stop, plan a structured approach with diet, resistance training and regular monitoring of weight, blood pressure and HbA1c if relevant. Sudden cessation rarely helps. A clinician-led plan does.

Is Wegovy cheaper than Mounjaro in 2026?

Wegovy (semaglutide) is generally cheaper per month than 15 mg Mounjaro in private pharmacies in 2026 but is broadly comparable in price to lower-dose Mounjaro. Head-to-head trial data shows tirzepatide outperforms semaglutide on weight loss at maximum doses. If switching for cost reasons, expect a clinical adjustment period and possibly slightly less weight loss. Decide with your prescriber based on goals and tolerability, not price alone.

When will oral GLP-1 tablets like orforglipron arrive in the UK?

Orforglipron is Eli Lillys non-peptide oral GLP-1. Phase 3 data has been strong and a regulatory decision is expected in 2026. Oral semaglutide 25 mg (a higher-dose tablet form of Wegovy) is also under review in 2026. If either is approved and priced competitively, the UK private GLP-1 market will likely become more competitive, since most patients prefer tablets to injections. UK availability dates depend on MHRA timing.

Is Mounjaro safe to use long term?

Trial data out to 72 weeks at the 15 mg dose has not shown new safety signals. Real-world UK safety data is reassuring on pancreatitis (low rates, mostly with confounding factors) but concerns remain about muscle and bone loss, especially in off-label use by non-obese people. The MHRA black triangle scheme is active, so any side effect should be reported via Yellow Card. Long-term outcome data beyond 3 years are still accruing.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.